MGN1703

DRUG4 trials

Sponsors

Mologen AG, University of Aarhus, M.D. Anderson Cancer Center

Conditions

Advanced CancersAdvanced Colorectal CarcinomaHIVMelanomaSmall Cell Lung Cancer

Phase 1

Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection

CompletedNCT02443935

University of AarhusHIV

Start: 2015-04-30End: 2017-06-25Updated: 2017-06-29

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

TerminatedNCT02668770

M.D. Anderson Cancer CenterAdvanced Cancers, Melanoma

Start: 2016-05-11End: 2025-11-05Updated: 2026-04-07

Phase 2

Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma

CompletedNCT01208194

Mologen AGAdvanced Colorectal Carcinoma

Start: 2010-06-30End: 2013-03-31Updated: 2014-06-20

Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

CompletedNCT02200081

Mologen AGSmall Cell Lung Cancer

Start: 2014-03-31End: 2017-10-05Updated: 2018-11-15

Related Papers

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology2025-02-061 citations

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

2019-07-0927 citations

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

Journal of Clinical Oncology2019-05-2014 citations

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals

AIDS2019-04-0188 citations

Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

Annals of Oncology2018-10-01

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

Clinical Infectious Diseases2017-03-03143 citations

A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.

Journal of Clinical Oncology2015-05-203 citations

Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.

Journal of Clinical Oncology2015-01-208 citations

IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.

Journal of Clinical Oncology2014-05-20